BeautyHealth's Q2 2024 results showed net sales of $90.6 million, a decrease of (22.9)% compared to the same period in 2023. This was due to lower equipment sales, partially offset by growth in consumables net sales. The company is addressing these challenges by offering lower-priced device options and additional financing solutions to providers.
Net sales were $90.6 million, a decrease of (22.9)% compared to Q2 2023, attributed to lower delivery systems net sales.
Gross margin was 45.2% compared to 57.8% in Q2 2023, with adjusted gross margin at 49.4% compared to 64.5% in Q2 2023, impacted by higher inventory related charges.
Net income was $0.2 million compared to $3.4 million in Q2 2023, primarily due to the gain on repurchase of convertible senior notes, partially offset by inventory related charges.
Adjusted EBITDA loss was $(5.2) million compared to adjusted EBITDA of $12.4 million in Q2 2023, mainly due to inventory related charges and lower net sales.
The company provided revised financial guidance for the third quarter and fiscal year 2024, reflecting continued pressure on delivery systems sales. It assumes no material deterioration in general market conditions and excludes any unannounced acquisitions, dispositions, or financings.
Visualization of income flow from segment revenue to net income